NEWS 114 FEED & ADDITIVE MAGAZINE July 2025 Entocycle, a specialist manufacturer of insect farming technology which uses insects to turn food waste into sustainable protein for animal feed, worked alongside Siemens to create the UK’s first digitalised insect farm showroom under four Victorian railway arches in the heart of London. The company, which designs and builds insect farms that convert food waste into low-carbon protein, strategically picked its central London location to attract talent and investors to its concept. Using Siemens' digital twin technology, Entocycle explains it was able to virtually model the facility before physical construction began, optimising the challenging arch-shaped space and preventing costly mistakes during the build phase. A full digital transformation was then undertaken, and the facility now leverages Siemens AI and automation to help scale operations while driving efficiencies. The advanced site features robotic arms, climate-controlled chambers and machine vision technology that counts and monitors 3,000 microscopic larvae a second with 96-100% accuracy. Implementing digitalisation has reportedly reduced insect larval growth time and improved survival rates by 30%, demonstrating how the emerging insect bioconversion process can be accelerated and implemented at industrial scale in the future. According to the announcement, after a year of successful operation at the site, the insect farm concept has proven how it can help address two critical sustainability challenges: Tackling the staggering 10.7 million tonnes of annual UK food waste (30% of which stems from supply chain inefficiencies) while simultaneously reducing dependency on the 3.3 million tonnes of imported soybean products that currently flood into the country each year for animal feed. Read more>> Siemens and Entocycle open insect farming technology hub Photo: Siemens Zivo Bioscience, Inc., a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, entered into a partnership with one of the world’s leading animal health companies, whose name has not been revealed yet, to advance Zivo’s novel immune-boosting compounds for use in multiple poultry market segments. The collaboration is expected to expand over time to address significant unmet needs in other livestock and companion animal species. Initially, Zivo and its partner have executed two agreements that will govern independent studies designed to validate and expand the use of Zivo’s proprietary actives as immune-enhancing biologics to complement existing poultry vaccination strategies. The first agreement covers a 42day study focused on coccidiosis, a parasitic disease that remains a major challenge to poultry producers worldwide. According to the announcement, this challenge study is intended to confirm previously demonstrated effects of Zivo’s compound now co-administered with the collaborator’s vaccine, and will include collecting tissue and plasma samples to evaluate performance parameters not previously examined. This trial will support the regulatory approval process of the USDA’s Center for Veterinary Biologics, as well as to validate the commercial business case and lead to a commercial agreement. Read more>> Zivo partnership targets poultry diseases Photo: Shutterstock | 2149210553
RkJQdWJsaXNoZXIy MTUxNjkxNQ==